CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies

Moomoo NewsNov 15 02:37 ET

CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A

MT NewswiresOct 25 07:07 ET

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Simply Wall StOct 2 19:40 ET

BeiHai Kangcheng-B (01228): CAN103 for the treatment of Gaucher's Disease (GD) qualifies for priority review.

Beihai Kangcheng-B (01228) announced CAN103 (Vilapine β) for the treatment of Gaucher's disease (GD)...

Zhitong FinanceSep 30 08:15 ET

Express News | CANbridge Pharmaceuticals Inc - Grant of Priority Review Status of Can103 for Treatment of Gaucher Disease

ReutersSep 30 08:14 ET

Beihai Kangcheng-B (01228.HK) appoints Fangxin Li as a non-executive director.

Grondragon September 30th |Beihai Kangcheng-B(01228.HK) announced that Fangxin Li has been appointed as a non-executive director and a member of the board of directors' remuneration committee, effective from September 30, 2024. The board of directors has also received the resignation letter of Hu Zhengguo as a non-executive director and a member of the board of directors' remuneration committee, effective from the date of effectiveness.

Gelonghui FinanceSep 30 05:41 ET